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Integrated analysis of germline and somatic
variants in ovarian cancer
Krishna L. Kanchi1,*, Kimberly J. Johnson1,2,3,*, Charles Lu1,*, Michael D. McLellan1, Mark D.M. Leiserson4,
Michael C. Wendl1,5,6, Qunyuan Zhang1,5, Daniel C. Koboldt1, Mingchao Xie1, Cyriac Kandoth1,
Joshua F. McMichael1, Matthew A. Wyczalkowski1, David E. Larson1,5, Heather K. Schmidt1,
Christopher A. Miller1, Robert S. Fulton1,5, Paul T. Spellman3, Elaine R. Mardis1,5,7, Todd E. Druley5,8,
Timothy A. Graubert7,9, Paul J. Goodfellow10, Benjamin J. Raphael4, Richard K. Wilson1,5,7 & Li Ding1,5,7,9
We report the ﬁrst large-scale exome-wide analysis of the combined germline–somatic
landscape in ovarian cancer. Here we analyse germline and somatic alterations in 429 ovarian
carcinoma cases and 557 controls. We identify 3,635 high conﬁdence, rare truncation and
22,953 missense variants with predicted functional impact. We ﬁnd germline truncation
variants and large deletions across Fanconi pathway genes in 20% of cases. Enrichment of
rare truncations is shown in BRCA1, BRCA2 and PALB2. In addition, we observe germline
truncation variants in genes not previously associated with ovarian cancer susceptibility (NF1,
MAP3K4, CDKN2B and MLL3). Evidence for loss of heterozygosity was found in 100 and 76%
of cases with germline BRCA1 and BRCA2 truncations, respectively. Germline–somatic inter-
action analysis combined with extensive bioinformatics annotation identiﬁes 222 candidate
functional germline truncation and missense variants, including two pathogenic BRCA1 and
1 TP53 deleterious variants. Finally, integrated analyses of germline and somatic variants
identify signiﬁcantly altered pathways, including the Fanconi, MAPK and MLL pathways.
DOI: 10.1038/ncomms4156
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O
varian cancer is diagnosed in B22,000 women annually
in the United States. The average 5-year survival is
relatively poor at B44% (ref. 1), which is primarily due
to late-stage diagnosis. It is currently estimated that 20–25% of
women have an inherited germline mutation that predisposes
them to ovarian cancer2,3. New strategies for the prevention and
control of ovarian cancer will rely on a thorough understanding
of the contributing genetic factors both at the germline and
somatic levels.
High-throughput sequencing technologies are rapidly expand-
ing our understanding of ovarian cancer biology by providing
comprehensive descriptions of genetic aberrations in tumours4.
The ability to rapidly sequence individual tumour and normal
genomes allows for efﬁcient discovery of candidate cancer-
causing events and such work is already transforming risk
assessment, diagnosis and treatment. For example, targeted
sequencing of 21 tumour suppressor genes in 360 cases of
ovarian, peritoneal, fallopian tube and synchronous ovarian/
endometrial carcinomas recently revealed that 24% of cases
harboured germline loss-of-function mutations in 1 of 12 genes:
BRCA1, BRCA2, BARD1, BRIP1, CHEK2, MRE11A, MSH6, NBN,
PALB2, RAD50, RAD51C and TP53 (ref. 3). In a different study,
the Cancer Genome Atlas (TCGA) consortium analysed somatic
alterations in 316 serous ovarian carcinomas, identifying
recurrent somatic TP53 mutations in nearly all cases (96%) and
ﬁnding recurrent somatic mutations in NF1, BRCA1, BRCA2, RB1
and CDK12 in a minority of cases4. Such work is deepening our
understanding of genes involved in ovarian cancer.
Cancer genomics studies have most often focused on
independent analyses of either somatic or germline mutations.
However, studies that perform sequencing of matched tumour
and normal samples have the advantage that data from the
somatic and germline genomes can be ascertained and integrated
to build a fuller picture of each genome’s contribution to disease.
In addition, the rapidly growing number of publicly available
exome data sets from non-cancer populations now facilitates rare
germline susceptibility variant discovery.
Here we describe the somatic and germline mutation spectrum
in the tumour and normal exome data from 429 TCGA serous
ovarian cancer patients. To identify candidate pathogenic
variants, we compare the frequency of germline mutations with
those from a large control data set of sequences of post-
menopausal women from the Women’s Health Initiative Exome
Sequencing Project (WHISP). We identify several novel candidate
germline predisposition variants in known ovarian genes (for
example, BRCA1, BRCA2, ATM, MSH3 and PALB2) as well as
several genes not previously associated with ovarian cancer (for
example, ASXL1, RB1, NF1, CDKN2A and EXO1). We also
characterize patterns of loss of heterozygosity (LOH) in tumour
suppressor genes, including BRCA1, BRCA2, BRIP1, ATM,
CHEK2 and PALB2, and identify signiﬁcantly mutated pathways,
including Fanconi anaemia, mitogen-activated protein kinase
(MAPK) and mixed lineage leukemia (MLL). These results
provide a foundation for future functional and clinical assessment
of susceptibility variants in ovarian cancer.
Results
Clinical characteristics of samples. Of the 429 TCGA cases in
this analysis, 90.2% were Caucasian (n¼ 387), 4.9% were African
American (n¼ 21), 3.5% were Asian (n¼ 15) and 0.5% (n¼ 2)
were American Indian/Alaska Native. Patients were diagnosed
between 26 and 89 years (mean 59.4±11.8 years), frequently at
late stage (93% at stages 3–4) and 50.8% were deceased at the time
of TCGA sample procurement (Table 1). Nineteen of 23 cases
with unknown ethnicity information were assigned Caucasian
(n¼ 17) and African ancestry (n¼ 2) using principal components
analysis (Supplementary Fig. 1). We performed systematic
germline variant and somatic mutation analyses for the sample
set, as illustrated in Fig. 1.
Data for 614 samples from the National Heart, Lung, and
Blood Institute (NHBLI) Women’s Health Initiative Exome
Sequencing Project WHISP were used for comparison of genetic
variants with TCGA ovarian cancer cases. After extensive quality
checks (Methods), 557 Caucasians with an average age of
63.3±7.8 years (range 50–79 years) were selected as controls
for downstream ovarian susceptibility variant analysis
(Supplementary Data 1).
Somatic mutations and signiﬁcantly mutated genes. We ana-
lysed somatic mutations in 429 ovarian cancer cases. Of these,
142 were new TCGA cases and 287 cases were previously
reported4; the remaining 29 cases reported in that study4 did not
meet our coverage requirement (Z20 coverage for at least 50%
of target exons) and were excluded from this analysis. The
average exome-wide coverage for the entire sample set was
68.1 with 99.5 and 96.5 average coverages for BRCA1 and
BRAC2, respectively. We identiﬁed 11,479 somatic mutations in
the 142 new TCGA cases. All of these mutations were manually
reviewed, resulting in a total of 27,280 mutations in 429 cases
(Fig. 1 and Supplementary Data 2 and 3). After removing genes
with low or no RNA expression evidence from RNA-seq data, the
signiﬁcantly mutated genes (SMGs) identiﬁed by MuSiC5 include
those previously reported: TP53, NF1, RB1, CDK12 (CRKRS) and
BRCA1 (ref. 4), as well as the new SMG, KRAS (Supplementary
Table 1). BRCA2 and RB1CC1 were near signiﬁcance. We also
identiﬁed 4 NRAS mutations, 3 NF2 mutations and 3, 8, and 10
mutations in the known tumour suppressor genes: ATR, ATM
and APC, respectively. Somatic truncation mutations were also
observed in histone modiﬁer genes including the following:
ARID1A, ARID1B, ARID2, SETD2, SETD4, SETD6, JARID1C,
MLL, MLL2 and MLL3 as well as the DNA excision repair gene
ERCC6 (Supplementary Data 3).
Germline variant landscapes and signiﬁcant germline events.
We identiﬁed germline truncation variants (nonsense, non-
stop, splice site and frameshift indels) in 429 matched tumour-
normal cases using multiple algorithms6–8. After removal of
Table 1 | Clinical characteristics of TCGA cases.
Category No. (%)
Ethnicity* Caucasians 387 (90.2)
African American 21 (4.9)
Asian 15 (3.5)
American Indian 2 (0.5)
Unknown 4 (0.9)
Survival Living 207 (48.3)
Deceased 218 (50.8)
Unknown 4 (0.9)









PCA, principal component analysis; TCGA, the Cancer Genome Atlas.
*Number assigned to each category after PCA analysis (Supplementary Fig. 1).
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common variants, reference sequence errors and recurrent
artifacts, a total of 3,635 high conﬁdence, rare (o1%
population minor allele frequency (MAF)) germline truncation
variants were identiﬁed in 2,214 genes, 115 of which are in 40
known cancer genes (Fig. 1, Supplementary Fig. 2; Supplementary
Data 4 and Methods)9. These 115 variants were validated using
genomic DNA or a source of whole-genome-ampliﬁed DNA
that differed from that used for discovery (Supplementary
Data 5). We used several approaches to identify known and
potentially pathogenic germline missense variants in the
Caucasian subset (Table 1, n¼ 387). Speciﬁcally, a total of
22,953 missense variants in 3,637 genes were predicted to be
functionally deleterious by Condel10 and also had population
MAFso1% in Caucasian data from the 1,000 Genomes, and the
current cohorts (TCGA ovarian cancer cases and WHISP exome
controls; Fig. 1, Supplementary Data 6 and Supplementary Fig. 3).
After limiting our analyses to genes with an average expression
Reads Per Kilobase per Million mapped reads (RPKM)40.5
(Methods), we identiﬁed 17,348 missense variants in a total of
2,810 genes in this subset. We processed 557 WHISP samples
using the same software tools and ﬁltering strategies and
identiﬁed 7,889 rare (o1% MAF in the population and cohort)
truncation variants and 30,335 rare missense variants deﬁned as
functionally deleterious by Condel and in expressed genes
(Supplementary Data 7 and 8).
Finally, although we performed a genome-wide germline copy-
number analysis using single nucleotide polymorphism (SNP)
array data, our manual review of the results indicated many false
positives with very few passing our review criteria. Therefore, we
focused our analysis of copy-number alterations on BRCA1,
BRCA2 and TP53, coupled with extensive manual review. Here
three high-conﬁdence germline deletion events in BRCA1 were
identiﬁed in three cases (TCGA-36-2539, TCGA-31-1959
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Figure 1 | Overview of the integrated analysis of germline and somatic variants in 429 TCGA serous ovarian cases. A total of 27,280 somatic mutations
were identiﬁed, including 6 SMGs (blue shaded area). Germline variants included a total of three BRCA1 large-scale deletions, following ﬁltering of
variants with 41% MAF in the population, TCGA ovarian cancer cases and WHISP controls; a total of 3,635 truncation variants and 22,953 missense
variants (17,348 in expressed genes) remained for TCGA cases. For WHISP controls, a total of 10,443 truncation and 30,335 missense variants
(in expressed genes) remained. After applying the burden test using WHISP exome sequence data, a total of 3 and 24 genes were signiﬁcantly enriched for
truncation events and missense variants, respectively (orange shaded area). The germline–somatic interaction analysis (purple shaded area) that
retained variants in expressed genes in ovarian cancer that met two out of ﬁve criteria identiﬁed a total of 222 candidate germline susceptibility variants.
The pathway analysis identiﬁed three signiﬁcant pathways involved in ovarian cancer pathogenesis, Fanconi, MAPK and MLL.
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TCGA-23-1028) developed ovarian cancer at younger ages
(50 and 43 years, respectively); information regarding age of
diagnosis for TCGA-36-2539 was not available.
We used a right-tailed cohort allelic sums test (CAST)11
burden test, CASTgreater (personal communication, Q.Z.), to
































































Figure 2 | Germline copy-number variants in BRCA1. Shown are three germline copy-number deletion variants affecting BRCA1 in three ovarian normal
tumour pairs. Normal samples appear above the corresponding tumour samples. Red lines indicate normalized copy-number segments based on a
minimum of eight probes, and blue dots indicate individual probe intensities from Affymetrix 6.0 SNP arrays within the region.
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enrichment of rare, potentially pathogenic missense variants in
the TCGA Caucasian exomes versus the WHISP control group
and the test identiﬁed 24 genes that had signiﬁcant enrichment
(Po0.0002, CASTgreater). As expected, BRCA1 was one of the
most signiﬁcant genes on the list (P¼ 1.40 E 06, CASTgreater). A
total of nine unique BRCA1 rare missense variants were detected
in this ovarian cancer cohort; this list included two known
pathogenic missense variants (R1699W and G1788V) and three
singletons (V772A, L668F and P1637L). It also included
one known ovarian cancer susceptibility gene (FANCM;
P¼ 4.04E 06, CASTgreater) as well as three cancer genes
(ARID1A, EGFR and DNMT1), not previously implicated in
ovarian cancer (Supplementary Data 6 and 9). ARID1A,
frequently mutated in endometrial cancer12, and EGFR, a
prominent oncogene involved in lung cancer13 and
glioblastoma14, harboured 10 and 5 rare (r1% MAF) unique
missense variants in this ovarian cancer sample set, respectively.
Several other known cancer genes (for example, CREBBP, ASXL1,
EZH2 and BRIP1) were also found to be in the top 100 and with
PCASTgreatero0.0015. The signiﬁcance of other top genes such as
EEF2K requires additional investigation using larger sample sets.
We next focused on comparison of rare germline truncations in
cancer genes between TCGA ovarian cases and the WHISP control
set. Three known ovarian cancer susceptibility genes were
signiﬁcant at the right-tailed CAST test with Pr0.05 as the
threshold (BRCA1 (P¼ 2E 08), BRCA2 (P¼ 8.89E 06) and
PALB2 (P¼ 0.042)) and two other known ovarian cancer
susceptibility genes were among the highest ranked genes, although
they did not reach signiﬁcance (CHEK2 (P¼ 0.11) and BRIP1
(P¼ 0.11)) (Supplementary Table 2). A total of 66 cases had
truncations in one of these genes (Supplementary Data 4 and 5). It
is noteworthy that we have identiﬁed truncation mutations in
USP6, ROPN1L and RYR1, although their involvements in cancer
are unclear. In addition, three truncation variants (T1222fs, Q645*
and L258fs) were detected in BLM, a gene recently linked to
familial breast cancer15. Q645* and L258fs were previously
reported in BLMbase (http://www.bioinf.uta.ﬁ/BLMbase/). The
distribution of germline and somatic mutations in these genes is
shown in Fig. 3. It is interesting to note that 11 cases had germline
truncation variants in multiple cancer genes, including two cases
with BRCA1 and BRCA2 variants (diagnosis ages 49 and 55 years),
one case with BRCA2 and ERCC3 variants, one with PALB2 and
ATM variants and one with BLM and FANCD2 truncation
variants. Finally, ﬁve cases had germline truncation variants in
other genes on the cancer gene list, including: ERCC2 (n¼ 1),
TET2 (n¼ 1), FANCD2 (n¼ 2) and NF1 (n¼ 1) while one case
had a germline mutation in RAD51B, which has recently been
linked to breast cancer susceptibility16 and whose family members
(RAD50, RAD51C and RAD51D) have previously been implicated
in ovarian cancer susceptibility17.
When we combined missense and truncation variants in cancer
genes for burden testing, known cancer susceptibility genes were
among the most signiﬁcant genes on the list (BRIP1 (refs 3,18)
and BRCA1). In addition, other established/suspected ovarian/
breast cancer susceptibility genes were signiﬁcant, including
BRCA2 (ref. 2) and NF1 (ref. 19); novel genes such as
ASXL1, frequently mutated in myelodysplastic syndromes20,
myeloproliferative neoplasms21 and AML22; SETD2, involved in
clear cell renal cell carcinoma23; and MAP3K1, a newly
discovered breast cancer gene24,25 (Supplementary Data 10).
Germline variants that have been detected as somatically
mutated in cancer might signal functional relevance of these
variants. We compared our identiﬁed germline truncation and
missense variants with those present in the COSMIC and OMIM
databases to determine whether any were reported in other
studies. Of the 3,635 exome-wide truncation variants, 84 and 10
germline variants matched precisely or within ±5 amino acids
to reported variants in COSMIC and OMIM, respectively
(Supplementary Data 11). Further analysis of 535 missense
variants from cancer genes, using the same criteria applied for
truncations, identiﬁed 35 and 14 missense events in COSMIC and
OMIM, respectively (Supplementary Data 11). For example, the
ASXL1 germline variant G1397S that we identiﬁed in 6 of 387
ovarian cancer cases versus 2 of 557 WHISP non-cases and the
ASXL1 germline variant G643V identiﬁed in 1 of 387 cases versus
0 of 557 WHISP non-cases have previously been found to be
somatically mutated in haematologic malignancies26,27. Although
there was not an exact match of the germline variant P333L in
TET2 in COSMIC (observed in 1 of 387 cases versus 0 of 557
WHISP non-cases), a somatic frameshift mutation, P333fs, was
reported by Metzeler et al.28 Another kinase domain germline
variant, D837N, in EGFR was absent in WHISP controls but
found in 5/387 ovarian cancer cases with a position matching a
reported somatic mutation (D837G) in COSMIC29.
Germline and somatic interactions in ovarian cancer. Since
familial cancer predisposition genes are also often somatically
mutated in non-familial cases30, we examined previously
characterized somatic SMGs (and BRCA2) that met our
expression criteria for putative germline functionally deleterious
variants (truncation and predicted deleterious missense) in the
germline data of ovarian cancer cases. As expected, a high
frequency of germline truncation variants was observed in BRCA1
(n¼ 32) and BRCA2 (n¼ 25). We observed one germline
truncation variant in NF1 (D290fs) in one case (age of
diagnosis: 39 years). We similarly investigated somatically
mutated protein tyrosine phosphatases and identiﬁed eight
germline truncation events in four genes (PTPN13, PTPRM,
PTPRR and PTPRH). Notably, four truncation events (two
H942fs, one R199fs and one T79fs) were found in PTPRH, a gene
not previously linked to ovarian cancer (Fig. 3). Analysis of
germline truncations in somatically mutated chromatin modiﬁer
genes also identiﬁed truncations in SETD4 (Y129fs), SETD6
(M264fs), MLL3 (exon 14-2), SMC5 (Q810fs) and SMC6 (Y954*).
This suggests a potential role for histone modiﬁers in ovarian
susceptibility and motivates further study. Predicted functionally
deleterious germline missense variants having low frequencies
were detected in several somatic SMGs, including BRCA1
(germline missense n¼ 27), BRCA2 (n¼ 13), NF1 (n¼ 8), RB1
(n¼ 3) and TP53 (n¼ 1; Supplementary Table 3). The two
patients having a germline V2148D variant in NF1 were
diagnosed at ages 36 and 45 years.
We further investigated the interplay between germline
variants (truncation and missense) and somatic mutations in
ovarian cancer, discovering 18 patients with germline truncation
variants and somatic mutations in the same gene (Supplementary
Table 4). For instance, a patient with a germline frameshift
mutation (M723fs) in PALB2 also harboured a somatic nonsense
mutation (Q378*) and another patient with a germline nonsense
variant (Q153*) in CDK5RAP1 acquired a somatic splice site
mutation in that gene (exon 9-2). We also detected eight patients
with both germline missense and somatic mutations from the
same cancer gene. This list includes two patients with BRCA1
(germline: R1347G and S1512I; somatic: E111* and G813fs), one
patient with NF1 (germline: A2644G; somatic: I85fs) and one
with TP53 (germline: G334R; somatic: P177R).
We investigated LOH in tumour samples for 535 missense
variants in cancer genes and 2,214 genes having germline
truncation variants (3,635) and found a total of 732 truncation
variants (63 in cancer genes) that displayed LOH in the tumour
samples (420% increase of variant allele frequency (VAF) over
normal was used for deﬁning LOH, considering the average 77%
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purity of the ovarian tumour cohort, false discovery rate¼ 22%,
Supplementary Fig. 5 and Methods), suggesting their potential
roles in ovarian cancer susceptibility (Fig. 4a,b and
Supplementary Data 12). Most notably, we observed at least a
20% increased VAF for 30/32 truncation mutations in BRCA1 (all
32 having increased VAFs) and 13/25 in BRCA2 (19 having
increased VAFs) in the tumour samples when compared with the
paired germline samples (Fig. 4c,d). In BRCA1, 13 LOH events
were associated with a loss of one copy in tumour (copy-number
segmentation mean r1.5), while nine LOH events were
associated with a single copy-number loss for BRCA2. We also
identiﬁed 14 BRCA1 and 4 BRCA2 copy-number neutral LOH
events in tumour samples (1.5ocopy-number segmentation
mean r2.5). A small number of cases carried germline
truncation variants with clear evidence of somatic LOH (loss of
the wild-type allele) in the tumour samples occurring in genes
involved in cell cycle checkpoint, Fanconi/DNA repair pathways
(for example, ATM, BRIP1, CHEK2, FANCA and MSH3), phos-
phatases (PTPRH and PTPRM) and a putative prostate cancer
susceptibility gene, ELAC2 (Fig. 4e and Supplementary Data 12).
This evidence suggests that several additional genes may be
associated with ovarian cancer susceptibility.
We examined LOH patterns indicating retained germline
missense variants in BRCA1. Here we identiﬁed two known
pathogenic missense variants, G1788V and R1699W31
(Supplementary Fig. 4); R1699W has VAFs of 42 and 79% and
G1788V has VAFs of 57 and 98% in the germline and tumour
samples, respectively. For one variant of unknown signiﬁcance,
S1521I, evidence indicating loss of the variant allele in the tumour
was present in 3/3 cases, suggesting that S1521I is not pathogenic,
in agreement with the Breast Cancer Information Core
classiﬁcation31. Evidence of LOH was inconsistent for R1347G
and R841W with 2/6 and 1/4 cases demonstrating LOH,
respectively. Three variants of unknown signiﬁcance (V772A,
P1637L and L668F) identiﬁed in single cases showed LOH. The
case with the V772A in BRCA1 was diagnosed with ovarian
cancer at age of 49 years; however, this case also carried a BRCA1
truncation variant. The case with the V1637L variant in BRCA1
also had a truncation in BRCA2 and V1637L has previously been
predicted to be functionally neutral32. For L688F that occurred in
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Figure 3 | Lolliplots showing the distribution of germline truncation variants and somatic mutations. Somatic mutations in BRCA1, BRCA2, PALB2,
CHEK2, BRIP1, BLM, MAP3K15 and PTPRH are shown in blue and germline truncation variants are in orange. Two known pathogenic BRCA1 germline missense
variants are also shown (G1788V and R1699W).
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Figure 4 | LOH analysis in tumour samples. (a) Scatter plot displaying variant allele frequencies for all germline truncation variants in normal and tumour
samples. Truncation variants in BRCA1 and BRCA2 are highlighted in red and blue, respectively. (b) Scatter plot displaying variant allele frequencies
for germline missense variants from cancer genes in normal and tumour samples. Germline missense variants in BRCA1 and BRCA2 are highlighted in red
and blue, respectively. (c) VAFs for the 32 samples showing LOH truncation in BRCA1, (d) VAFs for 25 samples showing LOH in BRCA2, (e) VAFs
in ATM, BLM, BRIP1, CHEK2, ERCC2, FANCA and PALB2. Overall, 100% (32/32) and 76% (19/25) of, respective, germline BRCA1 and BRCA2 truncation
variants showed increased VAFs in the tumour. All germline truncation variants in BRIP1 and CHEK2 also showed increased VAFs in corresponding tumours.
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one ovarian cancer case and was not observed in the WHISP data
set, no other truncation mutations were observed. None of the
BRCA2 missense variants were classiﬁed as clinically important in
the Breast Cancer Information Core BRCA2 database31,33.
Evidence of LOH for retaining some germline BRCA2 missense
variants (S1172L, T2088I, K2434T and A2951T) was observed
(Fig. 4d; Supplementary Fig. 4, and Supplementary Data 13). The
case harbouring K2434T in BRCA2 was diagnosed at the age of 37
years; however, further work is needed to conﬁrm the functional
relevance of such rare germline variants. We expanded our LOH
analysis to all rare missense variants across cancer genes
(Methods) and identiﬁed a total of 114 instances having a
greater than 20% increase of VAF in the tumour compared with
the germline (Fig. 4d and Supplementary Data 13).
We further employed germline–somatic interaction analyses
and extensive bioinformatics annotations to identify truncation
and missense variants with high likelihood of having functional
relevance. Speciﬁcally, we examined ﬁve aspects of each germline
variant (3,635 truncations and 535 missense): pfam annotation,
COSMIC/OMIM proximity match, LOH status, somatic SMG
status and somatic mutation in the same gene. When limiting our
candidates to variants meeting at least two of the ﬁve criteria, the
numbers of variants with putative functional effects decreased to
302 truncation and 56 missense events, respectively. In addition,
we limited our high conﬁdence variants to genes expressed
in ovarian cancer (RNA-Seq by expectation-maximization
(RSEM)40.5) and those that had a lower frequency in cases
than WHISP controls, thereby obtaining 222 putative variants
Table 2 | Thirty-ﬁve known and candidate functional missense variants.








Case Freq|| Control Freq|| LOFz
Fanconi
ATM p.R2459G NR NA NR NR 91.43 105 NA NA 1/387 (0.003) 0
ATM p.L480F NR NA NR NR 75.44 57 100 1 1/387 (0.003) 0 BRCA1
ATM p.P1112A NR NA NR NR 92.25 129 NA NA 1/387 (0.003) 0 BLM/
FANCD2













DM Ovarian cancer 98.16 217 95.65 46 1/387 (0.003) 0
BRCA1 p.V772A 4 /?,
3?/?,
1þ /?
Unknown DM Breast cancer 91.44 292 NA NA 1/387 (0.003) 0 BRCA1
BRCA2 p.A1996T NR Unknown NR — 7.14 14 NA NA 1/387 (0.003) 0
BRCA2 p.T2088I NR NR NR — 94.64 56 100 3 1/387 (0.003) 0
BRCA2 p.K2434T NR Unknown NR — 82.4 125 NA NA 1/387 (0.003) 0
BRCA2 p.F1241L NR NR NR — 13.46 52 NA NA 1/387 (0.003) 0
BRIP1 p.N370S NR NA NR — 76.66 377 0 1 1/387 (0.003) 0
BRIP1 p.P47A NR NA DM Breast cancer 97.71 436 100 12 1/387 (0.003) 1/557 (0.002)
BRIP1 p.A349P 1þ /? NA DM Fanconi anaemia 13.87 411 20 5 1/387 (0.003) 0
BRIP1 p.K703I NR NA NR — 88.29 205 100 2 1/387 (0.003) 0 BRIP1
CLTC p.R1498H NR NA NR — 93.06 72 98.15 379 1/387 (0.003) 1/557 (0.001)
ERCC2 p.R616P NR NA DM Trichothio dystrophy 75.25 101 NA NA 3/387 (0.008) 0
ERCC2 p.R616P NR NA DM Trichothio dystrophy 57.89 95 NA NA 3/387 (0.008) 0
ERCC2 p.R616P NR NA DM Trichothio dystrophy 53.97 63 48.39 31 3/387 (0.008) 0
ERCC2 p.A635V NR NA NR — 44.44 54 58.25 103 2/387 (0.005) 2/557 (0.003) BRCA2
ERCC2 p.A635V NR NA NR — 68.18 22 97.26 73 2/387 (0.005) 2/557 (0.003)
FRG1 p.G76V NR NA NR — 70.64 235 90.28 247 1/387 (0.003) 0 BRIP1
HIP1 p.T62M NA NR — 69.33 75 88.89 27 1/387 (0.003) 0 BRCA1
ITK p.R448H NR NA NR — 41.49 94 0 1 1/387 (0.003) 0
ITK p.R581W NR NA NR — 43.16 95 NA NA 1/387 (0.003) 1/557 (0.002)
MYH9 p.R1400W NR NA DM? Epstein syndrome 93.59 78 89.68 599 1/387 (0.003) 1/557 (0.002)
MYH9 p.D507N NR NA NR — 86.96 115 NA NA 1/387 (0.003) 1/557 (0.002)
NCKIPSD p.R677H NA NR — 85.71 14 92.73 55 1/387 (0.003) 0
NF1 p.V2148D NR NA NR — 41.67 12 0 61 2/387 (0.005) 0
NF1 p.V2148D NR NA NR — 35.71 14 0 76 2/387 (0.005) 0
NF1 p.A2644G NR NA NR — 8.28 145 10.84 83 1/387 (0.003) 0
NF1 p.P1421L NR NA NR — 89.04 146 81.82 11 1/387 (0.003) 0
NF1 p.R765H NR NA NR — 95.2 542 100 17 1/387 (0.003) 0
NOTCH2 p.H2032N NR NA NR — 36.78 87 49.28 414 2/387 (0.005) 1/557 (0.002) BLM
NOTCH2 p.H2032N NR NA NR — 86.59 82 92.95 241 2/387 (0.005) 1/557 (0.002)




NA NR — 39.95 388 58.86 157 1/387 (0.003) 1/557 (0.002)
RNF213 p.P978L NR NA NR — 82.76 29 100 2 1/387 (0.003) 0
SLC4A7 p.V824L NR NA NR — 85.71 35 100 5 1/387 (0.003) 0
TP53 p.G334R NR
(IARC)
NA NR — 83.95 81 NA NA 1/387 (0.003) 0
WAS p.E285Q NR NA NR E285X DM for
Wiskott–Aldrich
76.47 51 81.08 37 1/387 (0.003) 0
BIC, Breast Cancer Information Core; DM, disease causing mutation; Freq, frequency; HGMD, Human Gene Mutation Base; LOVD, Leiden Open Variation Database67; NA, not available; NR, not reported;
VAF, variant allele frequency.
These variants were identiﬁed using a combination of integrated germline and somatic analysis and bioinformatics annotation.
*LOVD67 key: numbers indicate number of LOVD reports. Variant pathogenicity is indicated, in the format Reported/Concluded; ‘þ ’ indicating the variant is pathogenic, ‘þ ?’ probably pathogenic, ‘ ’ no
known pathogenicity, ‘ ?’ probably no pathogenicity, ‘?’ effect unknown.
wBIC31 report (BRCA1 and BRCA2 only).
zHGMD68 status reported pathogenicity (DM).
yHGMD68 phenotype.
||Global Minor Allele Frequency.
zLoss-of-function truncation mutations in Fanconi pathway.
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with functional effects (181 truncations and 41 missense; Table 2
and Supplementary Data 14). After removing variants suspected
to be non-pathogenic based on previous published ﬁndings (ATM
F1463C34, BRCA1 L668F and P1637L32, PALB2 H1170Y35,
SMO36 and TSC2 (refs 37,38)), the missense list includes
variants from several genes including the two known pathogenic
BRCA1 variants (G1788V and R1699W), four BRIP1 variants,
three ATM variants, four NF1 variants and one TP53 variant
previously identiﬁed in breast cancer39 (Table 2). Notably, some of
the cases with variants identiﬁed through this analysis also had
truncation variants in known ovarian cancer predisposition genes
suggesting an alternative explanation or interacting risk alleles.
Our integrated analysis of germline and somatic variants identiﬁes
a set of known ovarian cancer susceptibility variants and
prioritizes a set of variants without previous association with
ovarian cancer susceptibility.
Signiﬁcant pathways in ovarian cancer. We performed pathway
analysis using PathScan statistical test40 including both germline
truncation variants and somatic mutations and identiﬁed the
Kyoto Encyclopedia of Genes and Genomes (KEGG) Fanconi
anaemia DNA repair pathway as signiﬁcant (P¼ 4.2E 08) along
with MAPK, cell cycle and TP53 signalling pathways (Fig. 5a and
Supplementary Data 15). RB/RAS pathways were previously
reported to be involved in ovarian cancer4. Germline and somatic
mutations in the Fanconi anaemia pathway affected a total of 40
genes in 37% (157/429) cases. Additional rare mutations detected
but not shown occurred in APITD1, EME1, ERCC1, HES1,
MLH1, PMS2CL, POLK, POLI, RAD51, REV3L, RMI1, RPA1,
RPA2, RPA4, TELO2, TOP3A, TOP3B, USP1 and WDR48.
We used HotNet41 to identify subnetworks of a genome-scale
protein–protein interaction network containing genes with
signiﬁcant numbers of somatic and germline variants. HotNet
identiﬁed two such subnetworks (Po0.01): one consisting of DNA
repair and Fanconi anaemia genes (Fig. 5a and Supplementary
Table 5) that is mutated in 33.1% (142/429) of samples. We
combined Fanconi genes from PathScan and HotNet analyses and





















































































































































Figure 5 | Signiﬁcant pathways and subnetworks in ovarian cancer. (a) Oncoprint of genes with germline truncation variants and somatic mutations
found in the Fanconi subnetwork identiﬁed as signiﬁcant by HotNet. Genes in the iRefIndex database58 are underlined. (b) The age distribution for
patients with or without germline alterations in Fanconi genes (genes include: a). The horizontal red line indicates the median age of the group and the blue
whiskers represent the age of the individual sample. (c) Oncoprint of genes with germline truncation variants and somatic mutations found in the
MAPK subnetwork identiﬁed as signiﬁcant by HotNet. Additional genes in the MAPK pathway with somatic mutations and/or germline truncation variants
are included. (d) Oncoprint of genes with germline truncation variants and somatic mutations found in a subnetwork including MLL, MLL3 and SETD1A
identiﬁed as signiﬁcant by HotNet. Additional chromatin modiﬁers with somatic mutations and/or germline truncation variants are included.
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study have germline/somatic defects in the Fanconi pathway. As
expected, we found that germline alterations in 47 Fanconi genes
are signiﬁcantly enriched in younger patients by a Wilcoxon rank-
sum test (427 tumours with data, P-value¼ 1.1878E 05, Fig. 5b).
A second subnetwork containing somatic mutations and
germline variants in EGFR, ERRB2, ERBB3 and other genes is
shown in (Fig. 5c and Supplementary Data 16). The frequency of
somatic mutations in each of these genes is low (o1.3%), as is the
frequency of germline variants (o0.3%). The signiﬁcance of this
subnetwork is thus derived from the combined analyses of
somatic mutations, germline variants and biological interactions
among these proteins. Using more permissive parameters,
HotNet identiﬁes two additional subnetworks (see Methods),
including a subnetwork containing MLL, MLL3 and SETD1A
(Fig. 5d and Supplementary Data 16). Mutations in these histone
methyltransferases have been previously reported in leukemias42,
breast cancer24 and renal carcinomas43 but have not been widely
reported in ovarian carcinoma.
Discussion
We report here the ﬁrst large-scale exome-wide analysis of the
combined germline–somatic landscape of ovarian cancer. We
used several analytic approaches to sift through millions of
germline variants to discover both known and candidate cancer
susceptibility genes and loss-of-function truncation and missense
variants. As expected, we found enrichment of germline
presumed loss-of-function truncation variants in the known
































































































































































Figure 5 | Continued.
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CHEK2 and PALB2. The average diagnosis age for patients with
germline BRCA1/BRCA2 truncation variants was 53.4 years,
signiﬁcantly younger than either patients with somatic BRCA1/
BRCA2 mutations (61.8 years, n¼ 32, P¼ 0.0002, t-test) or the
entire cohort (59.4 years, n¼ 427, P¼ 5.73E 06, t-test).
Interestingly, patients harbouring germline BRCA1/BRCA2
alterations have an average of 1.87 somatic mutations (n¼ 60)
in 127 SMGs from MuSiC analysis of 12 TCGA cancer types44
(curated from doi:10.1038/nature12634), which is markedly lower
than patients with somatic BRCA1/BRCA2 mutations (average of
2.84 somatic mutations, n¼ 32, P¼ 2.1E 05 t-test). Further,
likely loss-of-function truncation variants were detected in several
other genes/gene family members and syndromes (NF1) that
have previously been associated with breast and/or ovarian
cancer susceptibility including BLM15, FANCD2 (ref. 45), NF1
(refs 19,46), RAD51B47,48, FANCA49, FANCB, FANCL, FANCM,
ATRIP and ATR50. Notably, loss-of-function variants were
dispersed across a set of genes, in particular, previously
reported members of the Fanconi pathway51 and some novel
members.
The identiﬁcation of pathogenic missense variants in high-
throughput sequencing data is challenging owing to the large
number of rare variants of unknown signiﬁcance and inherent
uncertainties associated with in silico-based functional prediction.
To identify a set of known and likely pathogenic missense
variants, we used several complementary strategies including
LOH, COSMIC/OMIM proximity match, PFAM domain and
case/control allele frequency analyses. We ﬁrst applied the LOH
analysis to germline truncation variants in BRCA1 and BRCA2
and a small set of other tumour suppressor genes, demonstrating
a strong tendency to induce LOH of the wild-type allele in the
tumour. For example, clear evidence for LOH of BRCA1 wild-
type alleles in the tumour was present in virtually all cases, similar
to previous reports3,52. Further, our analysis identiﬁed two
pathogenic missense variants (G1788V and R1699W) as well as
three with uncertain pathogenicity (L668F, V772A and P1637L)
that demonstrated clear evidence of LOH. However, we note that
the single cases with V772A and P1637L variants each had a
BRCA1 truncation variant suggesting an alternative explanation
for these ﬁndings. LOH was also observed for several BRCA2
missense variants.
Evidence for pathogenicity was also demonstrated for a number
of variants in cancer genes including two pathogenic BRCA1, three
ATM and four BRIP1missense variants that met at least two of the
ﬁve criteria for classifying candidate pathogenic missense variants.
These results emphasize that integration of both somatic and
protein domain information can facilitate identiﬁcation of a set of
known and potentially pathogenic missense variants among
thousands of rare missense variants that informs functional
assessment of variants of unknown signiﬁcance.
Signiﬁcance analysis of germline truncation and missense
variants nominated a set of genes including ASXL1, MAP3K1
and SETD2 as candidate novel ovarian susceptibility genes.
COSMIC somatic mutation matches to ASXL1 germline missense
variant (G1397S) coupled with evidence for LOH support a
potential role for this variant in ovarian cancer susceptibility. In
addition, common variation in MAP3K1, another member of the
MAP3K family, has been associated with breast cancer suscept-
ibility53, was recently identiﬁed as a target of frequent somatic
breast cancer mutations24,25 and was signiﬁcant based on the
burden test.
Pathway and network analyses of the integrated collection of
germline and somatic variants revealed pathways with signiﬁcant
enrichment of variants including the Fanconi anaemia/DNA
repair pathway, MAPK pathway and histone methyltransferases.
In most cases, the individual genes in these pathways are altered
rarely by either germline or somatic variants, and it is only
through the combined analysis of both types of variants
across many genes that the alteration of these pathways
becomes apparent. This further emphasizes the extensive genetic
heterogeneity in serous ovarian carcinoma, as suggested by the
relatively small number of genes found to be recurrently mutated
by somatic mutations in TCGA study4.
We are mindful of limitations of TCGA and WHISP data for
germline analyses and the analysis of rare variants in general
including lack of family history information in TCGA cases that
would further inform these results, exclusion of women with a
prior malignancy that required systemic therapy from the TCGA
case set that might lead to an underestimation of the frequency of
germline susceptibility alleles in the population, lack of personal
cancer history information in WHISP controls, differences in
sequencing platforms used to generate the TCGA and WHISP
exome sequence data, and detection of rare germline variants that
are extremely rare/private and have no pathogenic signiﬁcance.
With respect to differences in sequencing platforms between the
case and control data sets, more variants were called in the
WHISP data than the TCGA data, which would reduce our ability
to detect signiﬁcantly higher frequencies of rare deleterious
germline variants in TCGA cases compared with WHISP
controls. In addition, it is noteworthy that the WHISP controls
were older on average than TCGA cases and were assembled for
the purpose of examining genetic susceptibility to non-cancer
outcomes. Therefore, pathogenic germline variants would most
likely be under-represented in this cohort, which would increase
our ability to identify pathogenic variants in TCGA ovarian
cancer cases.
In conclusion, this is the ﬁrst large scale and comprehensive
analysis of both germline and somatic exome variants in ovarian
cancer. Our exome-wide analysis strongly supports and extends
results from previous studies employing candidate gene
approaches for discovery of ovarian cancer genes, and is in line
with previous reports by identifying Fanconi anaemia pathway
genes as the most frequent targets of germline and somatic
mutations. Our integrated analyses of somatic and germline data
indicate additional genes and variants of potential importance in
ovarian cancer susceptibility for further investigation. In addition,
we emphasize that candidate variants and genes nominated by
our study will require extensive experimental functional valida-
tion as well as replication in additional ovarian cancer datasets.
Functionally validated variants will have important implications
for the development of screening strategies to evaluate ovarian
cancer predisposition.
Methods
Study population. We obtained approval from the database of Genotypes and
Phenotypes (dbGaP) to access the exome sequence and clinical data from TCGA
ovarian cancer cases for this study (document number 3281 Discover germline
cancer predisposition variants). We selected a total of 460 ovarian cancer cases (316
cases previously reported4 and 144 new ovarian cases) with their germline and
tumour DNA sequenced by exome capture followed by next-generation sequencing
on Illumina or SOLiD platforms. Of the 460 cases, 429 met our inclusion criteria of
50% coverage of targeted exome having at least 20 coverage in both germline
and tumour samples. Seventy-four percent of targets reached 20 coverage for
80% of breadth. Population estimates of allele frequencies were obtained from a
control group of 3,505 European individuals from the NHLBI exome data set
(https://esp.gs.washington.edu/drupal/), and from 379 European, 246 African, 286
ASN and 181 AMR descent individuals from the 1,000 genomes project54. The
global MAFs were obtained from the single nucleotide polymorphism (SNP)
database release 137, based on the 1,000 genomes phase 1 genotypes for 1,094
individuals, released on May 2011.
Ancestry classiﬁcation using PLINK. TCGA ovarian cancer cases were classiﬁed
with respect to ancestry using their SNP array data4 and the multi-dimensional
scaling analysis program in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/,
version 1.07). Five clusters were used for multi-dimensional scaling analysis.
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Twenty-three TCGA cases had unknown ethnicity information; we were able to
assign ethnicity for 19 of these as Caucasian (n¼ 17) and African American (n¼ 2)
using principal components analysis (Supplementary Fig. 1).
Control cohort. WHISP data for 614 samples were downloaded from dbGaP
(dbGaP Study Accession: phs000281.v4.p2), veriﬁed for ﬁle integrity, and then
imported as BAM ﬁles into our data warehouse. The WHISP data were collected as
part of the NHBLI Exome Sequencing Project that has the objective of detecting
genetic variants related to heart, lung and blood diseases as described at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000281.v4.p2.
Women included in WHISP were a subset of women who were part of the
Women’s Health Initiative55. To minimize batch differences between the ovarian
data set and these controls, we processed imported samples through the same
pipeline, including alignment to the GRCh37-lite reference sequence with BWA56
v0.5.9 with parameters –t 4 –q 5 and marking of duplicates by Picard v1.46. Single
nucleotide variants (SNVs) and indels were called using VarScan v2.2.9 (with
parameters --min-coverage 3 --min-var-freq 0.20 --P-value 0.10 --strand-ﬁlter 1 --
map-quality 10) with the false-positive ﬁlter57 and GATK58 v5336 (with
parameters -T IndelGenotyperV2 --window_size 300). Variant calls were restricted
to the B34Mbp CDS target region4.
To remove outliers in data quality, we required that WHISP samples have read
mapping rates o80%, duplication rates o40% and at least 10,000 SNVs called in
the target region. The 557 WHISP samples that met these criteria had, on average,
mapping rates of B95%, duplication rates of B9% and B18,000 SNVs called
in the target region. Eighty-one percent of targets reached 20 coverage for 80%
of breadth. These were used as controls in the downstream analysis.
Germline variant calling and ﬁltering. Sequence data from paired tumour and
germline samples were aligned independently to NCBI Build 36 of the human
reference using BWA 0.5.9 and de-duplicated using Picard 1.29. Germline SNPs and
indels were identiﬁed in paired BAMs using VarScan2 with the following parameters:
min-coverage¼ 30, min-var-freq¼ 0.08, normal-purity¼ 1, P-value¼ 0.10, somatic-
P-value¼ 0.001 and validation¼ 1. Additional germline SNPs were identiﬁed using
Samtools (version 0.1.7a (revision number 599) and additional germline indels were
identiﬁed using GATK (version 1.0 (revision 5336). All predicted variants were ﬁl-
tered to remove false positives related to potential homopolymer artifacts (variants
found in homopolymers having sequence length Z5 were removed), strand-speciﬁc
sequence artifacts, ambiguously mapped data (average mapping quality difference
between the reference supporting reads and variant supporting reads Z30) and low
quality data at the beginning and end of reads (variants supported exclusively by bases
observed in ﬁrst or last 10% of the reads). Variants having an allele frequencyo8%
were removed. Initial variant transcript annotation was based on a combined data-
base, including NCBI Refseq (May 2009) and Ensembl (version 54). All variants were
additionally annotated using (version 2.2) of Ensembl Variant Effect Predictor59.
Variants that occurred outside tier 1 (coding exons, canonical splice sites and RNA
genes) and variants that did not change the amino-acid sequence were not included in
the downstream analysis. Putative variants with translational effect were ﬁltered in the
multistep process shown in Supplementary Fig. 2 and described below. Variants were
ﬁltered if they either could not be mapped uniquely from NCBI build 36 to GRCh37,
were protein altering in a rare transcript that was exclusive to either the NCBI or
Ensembl database, or if they were non-synonymous only in transcripts that lacked a
valid open reading frame due to internal frame shifts, missing start codons and/or
missing stop codons. In addition, all variants were discarded from genes suspected to
have pseudogenes or other prologues missing from the human reference sequence,
such as PDE4DIP, CDC27, MUC4, DUX4 and XPC. We additionally ﬁltered variants
that occurred exclusively in non-coding RNA genes, those that affected only
predicted, hypothetical or olfactory genes, those that had a frequency41% in the
Caucasian population in the NHLBI GO exomes sequence data, those exclusively
within a transcript annotated as a pseudogene or processed pseudogene based on
Ensembl release (64) annotation downloaded via Biomart and ﬁnally those that were
reported as a validated somatic mutation in the same sample. Sequence data
supporting all remaining germline truncational variants were visually examined with
the Integrative Genomics Viewer60 and any data that appeared to be supported by
potential sequencing, ampliﬁcation or alignment artifacts were discarded. Additional
validated germline variants reported in BRCA1, BRCA2 were recovered, followed by
removal (ﬁltering) of any remaining non-synonymous germline variants that were
recurrent at the same position in more than 2% of the cohort (more than eight
samples at the same position). Finally, for the analysis of SMGs, genes not typically
expressed in ovarian adenocarcinoma tumour samples were ﬁltered if they had an
average RPKM r0.5. For the RNA-seq-based gene expression analysis, we used the
Pancan12 per-sample log2-RSEM matrix from doi:10.7303/syn1734155.1. A gene
qualiﬁed as expressed if it had at least three reads in at least 70% of samples. For every
gene, the average per-sample RSEM value was calculated across samples from the
same tumour type. The genes that had an average RSEMo0.5% were considered to
be low-expressed genes. Of the 20,239 genes that had an expression value in ovarian
cancer, 4,957 were low-expressed genes.
Cancer gene list. The cancer gene list (Supplementary Data 17) comprised of a
total of 672 unique genes of interest that included 436 genes from the Sanger
Cancer Gene9 list (http://www.sanger.ac.uk/genetics/CGP/Census/ as downloaded
on 1 December 2010), 41 uterine and endometrial cancer genes that we
previously identiﬁed as having recurrent somatic mutations12 and 50 genes that
have been identiﬁed in genome-wide association studies as containing
common cancer susceptibility variants to ovarian or breast cancer
(HugeNet, http://www.cdc.gov/genomics/about/index.htm). Of note, the 436 genes
on the Sanger cancer gene list contained gene clusters (IGH@, IGK@ and IGL@).
Individual genes from these clusters were extracted. Any genes on the list that
represented common fusion products of translocation or any gene that could not
be identiﬁed based on Ensembl release 58 and the corresponding release of NCBI
Refseq from the same time point were excluded. This process resulted in a total of
616 putative cancer-related genes.
Validation of truncation variants in cancer genes. We designed validation PCR
primers pairs using Primer3 and tailed the sequences with universal forward and
reverse primer sites. Primer pairs for PCR were selected to favour products with an
optimal size of 200–300 bp. (Supplementary Data 19 and 20) Larger or smaller
products were allowed to avoid problematic sequences. Alternate sources of whole
genome ampliﬁed (WGA) or original source genomic DNA samples from tumour
and normal pairs were ampliﬁed with PCR using a single-primer pair and each
individual PCR product was sequenced with BigDye Terminators using universal
primers. Products were puriﬁed and then loaded on an ABI 3730. Resulting reads
were base called using Phred, and aligned to genomic sequence representative of
the PCR products using Crossmatch. PolyScan61 and PolyPhred62 were used to
identify SNPs and Indels. Predicted putative rare germline variants were visually
reviewed using Consed to determine the exact position and sequence of indel
events and eliminate false positives due to data quality, LOH in the tumour sample,
artifacts resulting from sequence context, paralogue ampliﬁcation, or WGA or
Illumina library generation or sequencing artifacts.
Missense germline variant analysis. Missense germline variants were ﬁltered
using the same methods (Supplementary Fig. 3) previously described for germline
truncations. To minimize the number of variants tied with ancestral origins, only
missense germline variants from individuals classiﬁed as Caucasian by Plink were
used for downstream signiﬁcance testing. Missense germline variants were further
ﬁltered to retain only those identiﬁed as deleterious by the Ensembl implementa-
tion of Condel, a software program that employs a weighted approach to calculate
the functional impact of missense variants from scores calculated by SIFT63 and
PolyPhen-2 (ref. 64). We then removed missense germline variants that occurred at
41% frequency in the ovarian cancer cases and followed that by removing
germline predicted missense variants that were better classiﬁed as somatic variants.
Variants with population MAFs Z1% in NHLBI ESP GO exomes or 1,000
genomes were also ﬁltered. Remaining sites were annotated using the Ensembl
variant effect predictor instance of Condel and remaining predicted deleterious
variants were retained for burden analysis. Sites were further ﬁltered to only retain
expressed variants in cancer genes (as described above). In addition, we have
performed internal unbiased validation of all rare variants identiﬁed in 11 cases
using available whole-genome sequencing data that were independently generated.
It is noteworthy that whole-genome sequencing data for two cases were generated
using the SOLiD platform, furnishing orthogonal validation of the variants
discovered using Illumina sequencing data. (Supplementary Data 18).
We applied a modiﬁed version of the CAST11 to the ﬁnal list of germline
missense variants in the ovarian cancer data set to determine the statistical
signiﬁcance of deleterious variants in genes that were over-represented in ovarian
cases versus control exomes from the WHISP. A one-tailed CAST test was used to
identify only the genes with higher burden frequency in cases than in controls.
Germline copy-number alterations analysis. Segmented copy-number deletion
events were extracted from GISTIC (10.1073/pnas.0710052104) analysis of Affy-
metrix 6.0 SNP array data for a total of 426 exome sequenced tumour-normal
sample pairs with available array genotype data. Matched tumour and normal
samples were processed in parallel to identify putative germline copy-number
variations (CNV) with overlapping deletion segments deﬁned by eight consecutive
probes in both tumour and normal. Potentially truncating CNV deletion events in
the 672 cancer-related genes list were extracted from the total list. Graphical plots
were visually examined to identify and ﬁlter suspected artifacts and somatic copy-
number events. All CNV deletion events were annotated to identify those over-
lapping coding exons and those that were intronic, intergenic, or affected
untranslated region exons were removed. Matched tumour-normal exome capture
BAMs were examined to identify any heterozygous SNPs refuting germline copy-
number deletions or, alternatively, to identify coverage anomalies supporting the
presence of germline deletion events. Finally, individual probe intensities were
plotted and reviewed to remove additional artifacts.
LOH analysis. LOH analysis was performed by calculating the VAF of both SNV
and short indels using our internally developed tool bam-readcount (https://
github.com/genome/bam-readcount) for SNVs and Samtools mpileup6/VarScan7
for indels. Signiﬁcance testing was done on the basis of generating an approximate
empirical distribution of the actual population null distribution using a resampling
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method (bootstrapping with replacement). We corrected each case for tumour
purity using
VAFtumor;C¼VAFtumor;U ð1PtumorÞVAFnormalPtumor ð1Þ
where VAFtumour,C and VAFtumour,U are the corrected and uncorrected tumour
variant allele fractions, respectively, Ptumour is tumour purity and VAFnormal is
variant allele fraction in the normal. This equation is an algebraic consequence of
assuming that foreign variant and reference reads in the tumour are proportional
to their corresponding numbers in the normal sample. The distribution converged
within 108 trials (Supplementary Fig. S4) and this, in turn, agreed well with another
distribution model obtained by full enumeration of all possible VAF differences
within the data set. A threshold of 20, that is, Ptumour (VAFtumour–VAFnormal)
Z20%, was taken as signiﬁcant and this threshold incurs a false-positive error rate
of roughly a¼ 22%. The actual error rate may be slightly less because VAF
differences above 50 are, strictly speaking, spurious and probably due to
contamination in the normal.
Pathway analysis using HotNet. We applied HotNet65 to identify subnetworks in
a genome-scale protein–protein interaction network, each containing genes with
signiﬁcant numbers of somatic and germline aberrations. HotNet identiﬁes a list of
subnetworks, each containing at least s genes, and employs a two-stage statistical
test to assess the signiﬁcance of the list of subnetworks. We used HotNet version
1.1 and an interaction network from iRefIndex 9 (ref. 66) containing 212,746
interactions among 14,384 proteins, using parameter t¼ 0.05 to derive the
inﬂuence graph. With parameter d¼ 0.02, we ﬁnd two subnetworks
(Supplementary Table 5), each containing at least six genes (P¼ 0.0005). With
parameter d¼ 0.02, we ﬁnd four subnetworks (Supplementary Data 16), each
containing at least four genes (P¼ 0.1555).
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